Krebs Biochemicals & Industries Ltd.

As of June 30, 2026, Krebs Biochemicals & Industries Ltd. carries a market capitalization of 1.31B, placing it among publicly traded companies globally. Its enterprise value stands at 1.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Krebs Biochemicals & Industries Ltd. has 21.56M shares outstanding.

These figures are as of June 30, 2026.

These figures are as of June 30, 2026. The EV/Sales ratio of 5.19 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.31B versus a market cap of 1.31B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 1.47M in revenue per employee across its workforce of 172.00, a quick read on workforce productivity versus industry peers.

As of the close on October 23, 2026, Krebs Biochemicals & Industries Ltd.'s stock has declined approximately 23.31% over the past 52 weeks. The 50-day moving average sits at 57.15, while the 200-day moving average is 59.03.

Over the twelve months ended June 30, 2026, Krebs Biochemicals & Industries Ltd. generated 252.34M in revenue and converted that into -140.94M in net income, yielding earnings per share of -6.54. EBITDA reached -25.36M, while operating income came in at -89.48M.

Over the twelve months ended June 30, 2026, Krebs Biochemicals & Industries Ltd. posted a gross margin of 97.97, reflecting its pricing power and cost economics. The operating margin of -35.46 and net profit margin of -55.85 provide insight into operational efficiency.

Krebs Biochemicals & Industries Ltd.'s most recent stock split took place on January 31, 2019 with a 592:613 split ratio.